Seproxetine
Chemical compound
![]() |
|
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 4–16 days |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA ) | |
Chemical and physical data | |
Formula | C 16 H 16 F 3 N O |
Molar mass | 295.305 g·mol −1 |
This article
needs additional citations for
verification
.
Please help
improve this article
by
adding citations to reliable sources
. Unsourced material may be challenged and removed.
Find sources: "Seproxetine" – news · newspapers · books · scholar · JSTOR ( July 2019 ) ( Learn how and when to remove this template message ) |
Seproxetine , also known as ( S )-norfluoxetine , is a selective serotonin reuptake inhibitor (SSRI). [1] It is the S enantiomer of norfluoxetine, the main active metabolite of the widely used antidepressant fluoxetine ; but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, cardiac side effects were discovered [2] and development was discontinued. [1]
References
- 1 2 "Seproxetine" . DrugBank . University of Alberta . Retrieved 10 August 2016 .
- ↑ "Seproxetine" . Inxight Drugs . National Center for Advancing Translational Sciences (NCATS) . Retrieved 20 April 2023 .
Anxiolytics
(
N05B
)
|
|
---|---|
5-HT 1A R agonists | |
GABA A R PAMs |
|
Gabapentinoids
( α 2 δ VDCC blockers ) |
|
Antidepressants |
|
Sympatholytics
( Antiadrenergics ) |
|
Others | |
|
DAT
( DRIs ) |
|
|||||||
---|---|---|---|---|---|---|---|---|
NET
( NRIs ) |
|
|||||||
SERT
( SRIs ) |
|
|||||||
VMATs | ||||||||
Others |
|
|||||||
Corporate directors | |
---|---|
Products |
|
![]() |
This drug article relating to the nervous system is a stub . You can help Wikipedia by expanding it . |